刘诚

刘诚 is the Eureka Therapeutics founder and CEO interviewed in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学. The source presents him as a long-time [[CARTCellTherapy|CAR-T]] operator whose company began working on CAR-T in 2014 and focuses on late-stage solid tumors.

His main contribution to the wiki is a treatment-philosophy frame: cancer is difficult because it emerges from a body’s own cells, so therapies must solve the Cancer Immune Recognition Problem without simply damaging normal tissue. Liu treats CAR-T as a powerful route because it modifies immune cells to recognize and attack cancer, while still acknowledging cost, safety, [[SolidTumorCARTConstraints|solid-tumor barriers]], and regulatory risk.

Key Claims

• Liu distinguishes [[CARTCellTherapy|CAR-T]] from ordinary drugs by emphasizing that it is a living cell therapy using engineered immune cells.
• He argues that In Vivo CAR-T could solve much of the Ex Vivo CAR-T Manufacturing cost and time burden, but only if specificity and dose control become clinically reliable.
• He is skeptical that Allogeneic CAR-T can match autologous CAR-T because donor cells may be rejected and may not persist long enough.
• His 20-year cancer-cure forecast is defined as most people no longer dying from cancer or being unable to live normally with it, not as immediate universal eradication.

Connections

• Eureka Therapeutics - company he leads.
• CAR-T Cell Therapy, In Vivo CAR-T, Ex Vivo CAR-T Manufacturing, and Allogeneic CAR-T - technical routes he compares.
• Solid Tumor CAR-T Constraints, Tumor Microenvironment, and Cytokine Release Syndrome - main scientific and safety constraints he discusses.
• China Cell Therapy Regulatory Dual Track - regulatory and clinical-development context he explains for China.